4//SEC Filing
ANIDO ARMANDO 4
Accession 0001062993-23-018018
CIK 0001621443other
Filed
Sep 13, 8:00 PM ET
Accepted
Sep 14, 4:13 PM ET
Size
8.2 KB
Accession
0001062993-23-018018
Insider Transaction Report
Form 4
ANIDO ARMANDO
DirectorChairman & Chief Exec. Officer
Transactions
- Sale
Common Stock
2023-09-13$1.33/sh−17,830$23,637→ 936,722 total - Award
Common Stock
2023-09-12+64,747→ 954,552 total
Holdings
- 26,595(indirect: See footnote)
Common Stock
- 13,297(indirect: See footnote)
Common Stock
Footnotes (3)
- [F1]On September 12, 2023, the Compensation Committee of the Board of Directors of the Company determined that performance-vesting criteria were met with regard to 64,747 performance-based restricted stock awards granted in a prior year.
- [F2]This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
- [F3]TUA of Armando Anido and Nancy J. Anido Trusts are controlled by Armando Anido, who has voting and dispositive power with respect to shares held by the trusts.
Issuer
Zynerba Pharmaceuticals, Inc.
CIK 0001621443
Entity typeother
Related Parties
1- filerCIK 0001219866
Filing Metadata
- Form type
- 4
- Filed
- Sep 13, 8:00 PM ET
- Accepted
- Sep 14, 4:13 PM ET
- Size
- 8.2 KB